Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jan
15
Today In Oncology
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Machine Learning–Guided Optical Biopsy Accurately Identifies Malignant Lung Nodules Intraoperatively
Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer
Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors
SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo